Weitz Investment Management Inc. Purchases Shares of 40,800 Repligen Corporation $RGEN

Weitz Investment Management Inc. acquired a new stake in shares of Repligen Corporation (NASDAQ:RGEN) in the second quarter, HoldingsChannel.com reports. The institutional investor acquired 40,800 shares of the biotechnology company’s stock, valued at approximately $5,567,000.

Several other large investors have also modified their holdings of the stock. Bayforest Capital Ltd purchased a new stake in Repligen in the fourth quarter valued at approximately $32,000. Rachor Investment Advisory Services LLC purchased a new position in Repligen during the fourth quarter worth approximately $33,000. Measured Wealth Private Client Group LLC acquired a new position in shares of Repligen in the 3rd quarter valued at $29,000. Los Angeles Capital Management LLC acquired a new position in shares of Repligen in the 4th quarter valued at $36,000. Finally, Farther Finance Advisors LLC boosted its holdings in shares of Repligen by 61.8% in the 4th quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 128 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Repligen Stock Up 0.5%

NASDAQ RGEN opened at $181.13 on Friday. The company has a quick ratio of 7.64, a current ratio of 9.05 and a debt-to-equity ratio of 0.26. Repligen Corporation has a fifty-two week low of $100.99 and a fifty-two week high of $188.73. The business has a 50 day moving average price of $147.16 and a two-hundred day moving average price of $131.88. The stock has a market cap of $10.22 billion, a PE ratio of 248.12, a P/E/G ratio of 3.31 and a beta of 1.03.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.45 by $0.09. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The company had revenue of $204.13 million for the quarter, compared to analyst estimates of $201.59 million. During the same quarter last year, the firm posted $0.26 earnings per share. The business’s quarterly revenue was up 11.9% on a year-over-year basis. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. As a group, sell-side analysts predict that Repligen Corporation will post 2.06 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on RGEN. Wells Fargo & Company upped their price objective on Repligen from $180.00 to $185.00 and gave the stock an “overweight” rating in a report on Thursday, July 30th. Wolfe Research began coverage on Repligen in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $145.00 target price on the stock. Evercore reissued an “outperform” rating and set a $160.00 price target on shares of Repligen in a research report on Monday, July 6th. Barclays upped their price target on Repligen from $145.00 to $160.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 6th. Finally, Jefferies Financial Group restated a “hold” rating and issued a $142.00 price objective on shares of Repligen in a report on Tuesday, May 5th. Three analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $166.43.

Insiders Place Their Bets

In related news, CFO Jason K. Garland sold 733 shares of the firm’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $145.00, for a total transaction of $106,285.00. Following the completion of the sale, the chief financial officer directly owned 19,359 shares of the company’s stock, valued at approximately $2,807,055. This trade represents a 3.65% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.60% of the company’s stock.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.